You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

February 26, 2013

Online Pharmacies in Thailand: Potential Risks

Informed Counsel

“Save 30% if you buy today!” This is just one of many familiar e-commerce advertisements that regularly bombard consumers online. By employing many of the same techniques that have proven to be successful in selling other goods, many online pharmacies advertise drugs in an aggressive fashion to increase their sales.

Of course, online pharmacies offer certain advantages. They help consumers find the specific drug products they need, and they often offer special discounts. Online pharmacies are also easy to access—a simple web search reveals a seemingly endless list of online pharmacies. Furthermore, if a customer feels embarrassed about purchasing certain types of products, such as erectile dysfunction medication, from an actual pharmacy, a virtual pharmacy can help prevent an uncomfortable experience.

But despite these conveniences, there are some important risks associated with online pharmacies and the products they sell. Large quantities of drugs can be dispensed, which may raise the possibility of drug abuse. A further important risk is posed by counterfeit medication; drug products purchased online may be counterfeit, illegal, or unapproved by Thailand’s Food and Drug Administration (FDA).

Web Pharmacy Hosted in Thailand: Illegal Products and Consequences

The Pittsburgh Post-Gazette published a story about a 33-year-old Thai woman who was the head of a company running a website, www.eDrugnet.com, plus at least 30 other affiliated websites. These sites sold drugs without prescriptions, despite the fact that they were required. These e-pharmacy websites were hosted in Thailand and shipped drugs to the United States. The company received e-mails with drug orders from customers and would send drugs overseas in boxes labeled as samples and gifts via express mail.

After a lengthy investigation by the U.S. FDA, FBI, and Department of Homeland Security, which involved meeting the woman in Bangkok and ultimately causing her to fly to the United States to meet undercover agents, the woman confessed to the scheme. She pleaded guilty in federal court to wire fraud, money laundering, and introducing misbranded drugs to the United States. The Thai businesswoman is suspected of having made over USD 2.1 million. Her website has been taken offline, and her income and the assets from the business could be seized following the court sentencing, which is set for February 22, 2013.

Legislation in Thailand Governing Online Pharmacies

There is no separate legislation governing the online sale of pharmaceutical products through web pharmacies hosted in Thailand. The Drug Act B.E. 2510 (1967), which is applicable to the physical sale of medicinal and pharmaceutical products, also regulates the online sale of such products.

According to Section 14 of the Drug Act, the licensing authority (the Thai FDA) will approve a “license to sell drugs” for business operators if they comply with certain requirements. One of the requirements is that the business operator, a resident in Thailand, has the premises to sell or store drugs, equipment for use in the sale or storage of drugs, and control over the maintenance of drug quality and quantity, as prescribed in the ministerial regulations. In addition, Section 21 of the Drug Act states that a business operator that has been permitted to sell modern drugs must have a pharmacist on duty during business hours. These two sections of the Drug Act restrict the distribution of drugs “virtually,” since both the requirements of appropriate premises and a pharmacist on duty are unmet.

Using the Internet and Social Media for Drug Advertising

Despite the fact that it is not legal under Thai law to market drug products online, more and more pharmacies are now turning to social media marketing as a promotional channel. Many pharmacies are creating fan pages via social media as part of a “direct-to-consumer advertising” strategy.

However, business operators need to understand that information distributed on the internet, intended for customers in Thailand, must meet the same requirements as other media distribution. While there are no specific rules on the use of the internet or social media for drug advertisements, the Thai FDA enforces and regulates the promotion of drugs via Sections 88 to 90 of the Drug Act. Under Section 88 bis, advertisements to sell drugs via radio, television, movies, or through printed matter must receive permission from the Thai FDA for the text, sound, or picture used in the advertisement.

Nevertheless, most advertisements (more than 85 percent) on the internet are being presented without permission, according to the Thai FDA. Currently, the FDA has made it a priority to deal with this problem. Thus, business operators must ensure that their social media marketing strategy meets FDA requirements, as well as the requirements of the Drug Act. Any violation of the Drug Act’s marketing provision is subject to a fine of up to THB 100,000 (USD 3,330).

Increasing Enforcement

Thailand’s current drug laws are more than forty years old, and therefore are not well suited to deal with e-commerce. Although it is not legally permissible to market drug products online in Thailand, the illegal online pharmacies that do still exist pose threats to consumers in regard to the method of distribution, which may increase the likelihood of drug abuse, and further run the risk of medication being counterfeit. Thai pharmaceutical businesses should assess whether their e-commerce and marketing activities violate drug laws, especially as national and international authorities are stepping up their efforts to prevent the further proliferation of illegal online pharmacies.

RELATED INSIGHTS​ 

October 15, 2025
The Indonesian Food and Drug Administration (BPOM) has introduced more stringent oversight of health supplements containing probiotics with new guidelines that require clinical trials for certain products and expanded documentation standards. BPOM Regulation No. 17 of 2025 replaces the previous 2021 regulation and establishes a comprehensive framework for evaluating probiotic strains used in health supplements. Assessment Requirements The new regulation expands the scope of assessment to include not only categorization and documentation but also technical procedures, strain classification, and clinical trial requirements. Unlike the previous regulation, which provided general guidance, the updated framework creates a comprehensive system for evaluating both registered probiotic strains and new or combined strains. Manufacturers must now submit supporting documentation covering strain identification and functional characterization, safety, efficacy, and product quality. The previous regulation required documentation only on safety, efficacy, and quality. Clinical Trials One of the most significant changes is the requirement for clinical trials conducted in Indonesia for applications that include benefit claims other than maintaining digestive health, or where there are modifications to benefit claims. The regulation specifies that phase 1 trials must demonstrate safety, while phase 2 trials must validate efficacy using statistically valid methods such as double-blind, randomized, placebo-controlled studies). In addition, phase 3 and phase 4 trials may be required, and postmarket surveillance data must be submitted. Technical Assessment Framework Annex 4, a newly introduced section, establishes technical procedures for assessing health supplements containing probiotics in Indonesia. This comprehensive framework outlines criteria for evaluating new probiotic strains, including strain identification, functional characterization, safety, efficacy, and product quality. The annex introduces a clear classification of claims for health supplement products containing probiotics: General claims(e.g., maintaining digestive health). Functional claims(e.g., normal biological function or activity in the body). Risk reduction claims(e.g., lowering disease risk). The regulation restricts use of the term
October 3, 2025
On September 26, 2025, the Contract Committee under Thailand’s Consumer Protection Board issued a regulation that aims to standardize contracts and enhance consumer protection within the beauty and wellness industry. The Notification on Prescribing the Beauty Service Business as a Contract-Controlled Business B.E. 2568 (2025), which takes effect on January 24, 2026, requires business operators to use a prescribed standard contract in Thai and adhere to strict mandatory provisions and prohibitions. These regulations apply to operators across all in-person and online service channels, including via digital platforms. “Beauty services business” is defined as the provision of services under an agreement allowing consumers to receive a series of treatments, either over a set number of sessions or within a set period. This includes massage, spa, other methods for cleanliness, beauty, or care of facial or body skin, and weight control and body shaping—including services offered electronically. The law excludes surgery, liposuction, and medical treatments performed by licensed practitioners. The notification establishes the following key requirements: Mandatory contract and formatting. All contracts with consumers must use the standard contract form, in Thai, with clear, readable text (minimum font size of 2 millimeters, no more than 11 characters per inch), and include all essential terms from the annexed form. Contract execution. Contracts must be made in duplicate, with one copy given to the consumer at signing. For agreements concluded through electronic channels, the process must comply with the Electronic Transactions Act and use the same required terms. Digital platforms. Business operators who provide services facilitated through a digital platform as an intermediary are ultimately responsible for ensuring the consumer receives a compliant contract. Prohibited clauses. The law prohibits clauses that limit or exclude liability for damages to life, body, health, mind, or property resulting from breach of contract or a wrongful act;
September 16, 2025
Since Thailand formally removed Mitragyna speciosa (kratom) from the list of narcotic drugs, the country has progressed from outright prohibition to a structured, license-based regime. While the Ministry of Public Health oversees cannabis plant regulation, the Ministry of Justice (MOJ) is the regulatory authority overseeing kratom plants. For the avoidance of doubt, separate Ministry of Public Health notifications prohibit the use of kratom as a food ingredient unless a food safety evaluation has been conducted; however, this restriction does not affect trade in unprocessed leaves per se. For businesses in Thailand dealing exclusively in kratom leaves, the most consequential development is the Ministerial Regulation on the Application for Permits and Notifications for the Importation and Exportation of Kratom Leaves B.E. 2568 (2025), a bylaw of the Kratom Plant Act 2022. The ministerial regulation establishes the following notable definitions: “Kratom leaves”: Fresh or dried leaves in their natural, unprocessed state (no extracts, concentrates, or infused products). “Import/Export”: Any act of bringing kratom leaves into or out of Thailand, whether for commercial sale, industrial processing abroad, or research. Import/Export Licensing Under the Kratom Plant Act, a license is mandatory for importing or exporting kratom leaves. Individuals, juristic persons, community enterprises, and state agencies in Thailand are eligible to obtain a license to import (or a license to export) kratom leaves. Licenses are available to qualified individuals and juristic persons. Individuals must satisfy the following qualifications to be eligible for a license: Thai nationality, ≥ 20 years old, resident in Thailand. Not incompetent, quasi-incompetent, or under legal guardianship. No license suspension currently in force under the Kratom Act or Narcotics Code. No license revocation in the previous two years. No conviction under the Kratom Act or Narcotics Code within the previous two years (unless fully released from punishment). Juristic persons must satisfy
September 4, 2025
With advancements in health technology, telemedicine has taken on a wider online presence in Thailand. Under the Medical Facility Act, licensed clinics and hospitals may now diagnose, prescribe, and issue electronic prescriptions during a video call, provided they maintain patient confidentiality and proper recordkeeping. As a complementary concept, a telepharmacy allows a pharmacist to verify prescriptions, counsel patients, and dispense medication from a remote site. Hospitals, clinic chains, and some retail pharmacy groups have adopted “drive-thru” or “locker” pick-up points where drugs are bagged only after a real-time video consultation with a registered pharmacist. The clear benefits of telehealth include shorter waiting times and broader access to specialists, which is in the public interest. Drug Distribution and Advertising in Thailand The online pharmacy ecosystem creates a legal bridge in that once a teleconsulting doctor issues an e-prescription, a licensed pharmacy can lawfully dispense and deliver the medicine prescribed to the patient’s door. Nonetheless, the critical compliance component remains the advertising of medicinal drugs. It is still not allowed to advertise prescription/pharmacy-dispensed drugs to the public in Thailand. Although Thailand’s Drug Act of 1967 was written more than half a century ago, it still governs the trading of every medicinal drug that makes its way to consumers in Thailand—whether bought at a pharmacy or delivered with a few taps on a smartphone. First and foremost, the pharmacy must hold a license to sell medicinal drugs as a retailer. It is also mandatory that arrangements be made for a pharmacist to be on duty during opening hours. Drugs are classified into three main categories: prescription drugs, pharmacy-dispensed drugs, and over-the-counter (OTC) drugs. The listing of OTC drugs with their prices via an online platform is allowed, as only OTC drugs may be advertised directly to the public. However, naming or showing